MEK Inhibitor Mirdametinib (PD-0325901) in Patients With Neurofibromatosis Type 1 Associated Plexiform Neurofibromas
Public ClinicalTrials.gov record NCT03962543. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 2b Trial of the MEK 1/2 Inhibitor (MEKi) PD-0325901 in Adult and Pediatric Patients With Neurofibromatosis Type 1 (NF1)-Associated Inoperable Plexiform Neurofibromas (PNs) That Are Causing Significant Morbidity
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This study evaluates mirdametinib (PD-0325901) in the treatment of symptomatic inoperable neurofibromatosis type-1 (NF1)-associated plexiform neurofibromas (PNs). All participants will receive mirdametinib (PD-0325901). Eligible participants may continue in a long-term follow-up phase.
Study identification
- NCT ID
- NCT03962543
- Recruitment status
- Active, not recruiting
- Study type
- Interventional
- Phase
- Phase 2
- Lead sponsor
- SpringWorks Therapeutics, Inc., a healthcare company of Merck KGaA, Darmstadt, Germany
- Industry
- Enrollment
- 114 participants
Conditions and interventions
Eligibility (public fields only)
- Age range
- 2 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Sep 28, 2019
- Primary completion
- Sep 19, 2023
- Completion
- Dec 21, 2028
- Last update posted
- Jul 9, 2026
2019 – 2028
United States locations
- U.S. sites
- 43
- U.S. states
- 25
- U.S. cities
- 40
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| University of Alabama at Birmingham/Children's of Alabama | Birmingham | Alabama | 35233 | — |
| Mayo Clinic Arizona | Phoenix | Arizona | 98195 | — |
| Arkansas Children's Hospital | Little Rock | Arkansas | 72202 | — |
| Children's Hospital Los Angeles | Los Angeles | California | 90027 | — |
| University of California, Los Angeles (UCLA) | Los Angeles | California | 90095 | — |
| Children's Hospital of Orange County | Orange | California | 92868 | — |
| University of California - Irvine Health | Orange | California | 92868 | — |
| Lucile Packard Children's Hospital Stanford | Palo Alto | California | 94304 | — |
| University of California - Davis | Sacramento | California | 95817 | — |
| Children's Hospital Colorado | Aurora | Colorado | 80045 | — |
| Nemours A. I. duPont Hospital for Children | Wilmington | Delaware | 19803 | — |
| Children's National Hospital | Washington D.C. | District of Columbia | 20010 | — |
| University of Florida Clinical Research Center | Gainesville | Florida | 32610 | — |
| Nicklaus Children's Hospital | Miami | Florida | 33155 | — |
| Florida Hospital Cancer Institute | Orlando | Florida | 32804 | — |
| Arnold Palmer Hospital for Children | Orlando | Florida | 32806 | — |
| Johns Hopkins All Children's Hospital | St. Petersburg | Florida | 33701 | — |
| Moffitt | Tampa | Florida | 33612 | — |
| University of Illinois Hospital and Health Systems | Chicago | Illinois | 60612 | — |
| Indiana University | Indianapolis | Indiana | 46202 | — |
| University of Iowa Health Care | Iowa City | Iowa | 52242 | — |
| University of Michigan Comprehensive Cancer Center | Ann Arbor | Michigan | 48109 | — |
| Henry Ford Hospital | Detroit | Michigan | 48202 | — |
| University of Minnesota/Masonic Cancer Center | Minneapolis | Minnesota | 55455 | — |
| Mayo Clinic | Rochester | Minnesota | 55905 | — |
| Washington University | St Louis | Missouri | 63110 | — |
| Saint Joseph's Regional Medical Center | Paterson | New Jersey | 07503 | — |
| Albany Medical Center | Albany | New York | 12208 | — |
| Children's Hospital at Montefiore | The Bronx | New York | 10467 | — |
| UNC Medical Center | Chapel Hill | North Carolina | 27599 | — |
| Duke University Medical Center | Durham | North Carolina | 27710 | — |
| UC Health | Cincinnati | Ohio | 45219 | — |
| Nationwide Children's Hospital | Columbus | Ohio | 43205 | — |
| University of Oklahoma - Health Sciences Center | Oklahoma City | Oklahoma | 73104 | — |
| Oregon Health and Science University | Portland | Oregon | 97239 | — |
| Children's Hospital of Pittsburgh UPMC | Pittsburgh | Pennsylvania | 15219-2739 | — |
| Vanderbilt Children's Hospital | Nashville | Tennessee | 37232 | — |
| University of Texas Southwestern | Dallas | Texas | 75244 | — |
| Cook Children's Medical Center | Fort Worth | Texas | 76104 | — |
| MD Anderson Cancer Center | Houston | Texas | 77030 | — |
| The University of Utah Health Sciences Center | Salt Lake City | Utah | 84108 | — |
| University of Virginia - Emily Couric Cancer Center | Charlottesville | Virginia | 22903 | — |
| Children's Hospital of The King's Daughters | Norfolk | Virginia | 23510 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT03962543, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jul 9, 2026 · Synced Sep 9, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT03962543 live on ClinicalTrials.gov.